Literature DB >> 11099472

Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression.

H Q Miao1, P Lee, H Lin, S Soker, M Klagsbrun.   

Abstract

Neuropilin-1 (NRP1) is a VEGF(165) and semaphorin receptor expressed by vascular endothelial cells (EC) and tumor cells. The function of NRP1 in tumor cells is unknown. NRP1 was overexpressed in Dunning rat prostate carcinoma AT2.1 cells using a tetracycline-inducible promoter. Concomitant with increased NRP1 expression in response to a tetracycline homologue, doxycycline (Dox), basal cell motility, and VEGF(165) binding were increased three- to fourfold in vitro. However, induction of NRP1 did not affect tumor cell proliferation. When rats injected with AT2.1/NRP1 tumor cells were fed Dox, NRP1 synthesis was induced in vivo and AT2.1 cell tumor size was increased 2.5- to 7-fold in a 3-4 wk period compared to controls. The larger tumors with induced NRP1 expression were characterized by markedly increased microvessel density, increased proliferating EC, dilated blood vessels, and notably less tumor cell apoptosis compared to noninduced controls. It was concluded that NRP1 expression results in enlarged tumors associated with substantially enhanced tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099472     DOI: 10.1096/fj.00-0250com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  79 in total

1.  Rous-Whipple Award Lecture. How tumors make bad blood vessels and stroma.

Authors:  Harold F Dvorak
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

2.  Neuropilin-2 regulates α6β1 integrin in the formation of focal adhesions and signaling.

Authors:  Hira Lal Goel; Bryan Pursell; Clive Standley; Kevin Fogarty; Arthur M Mercurio
Journal:  J Cell Sci       Date:  2012-02-02       Impact factor: 5.285

Review 3.  Neuropilin Functions as an Essential Cell Surface Receptor.

Authors:  Hou-Fu Guo; Craig W Vander Kooi
Journal:  J Biol Chem       Date:  2015-10-08       Impact factor: 5.157

4.  Peptide-targeted, stimuli-responsive polymersomes for delivering a cancer stemness inhibitor to cancer stem cell microtumors.

Authors:  Fataneh Karandish; James Froberg; Pawel Borowicz; John C Wilkinson; Yongki Choi; Sanku Mallik
Journal:  Colloids Surf B Biointerfaces       Date:  2017-12-24       Impact factor: 5.268

5.  The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors.

Authors:  Mukaddes Izci; Christy Maksoudian; Bella B Manshian; Stefaan J Soenen
Journal:  Chem Rev       Date:  2021-01-14       Impact factor: 60.622

6.  All vessels are not created equal.

Authors:  Diane R Bielenberg; Patricia A D'Amore
Journal:  Am J Pathol       Date:  2013-02-17       Impact factor: 4.307

7.  Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry.

Authors:  David Ghez; Yves Lepelletier; Sophie Lambert; Jean-Marie Fourneau; Vincent Blot; Sébastien Janvier; Bertrand Arnulf; Peter M van Endert; Nikolaus Heveker; Claudine Pique; Olivier Hermine
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

8.  Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish.

Authors:  Percy Lee; Katsutoshi Goishi; Alan J Davidson; Robert Mannix; Leonard Zon; Michael Klagsbrun
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-25       Impact factor: 11.205

9.  Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity.

Authors:  H Jia; L Cheng; M Tickner; A Bagherzadeh; D Selwood; I Zachary
Journal:  Br J Cancer       Date:  2010-01-19       Impact factor: 7.640

10.  Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Authors:  Shumin Zhang; Haiyen E Zhau; Adeboye O Osunkoya; Shareen Iqbal; Xiaojian Yang; Songqing Fan; Zhengjia Chen; Ruoxiang Wang; Fray F Marshall; Leland W K Chung; Daqing Wu
Journal:  Mol Cancer       Date:  2010-01-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.